Atossa Therapeutics, Inc. (ATOS)

Atossa Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	13.5	14.04	12.61	11.31	8
Research & Development	14.12	17.33	15.08	9.21	6.61
Operating Expenses	27.62	31.38	27.69	20.52	14.61
Operating Income	-27.62	-31.38	-27.69	-20.52	-14.61
Interest & Investment Income	4.05	4.34	0.88	0.01	-
Other Non Operating Income (Expenses)	-0.22	-0.07	-0.15	-0.09	-3.22
EBT Excluding Unusual Items	-23.79	-27.1	-26.96	-20.61	-17.83
Gain (Loss) on Sale of Investments	-1.71	-2.99	-	-	-
Pretax Income	-25.5	-30.09	-26.96	-20.61	-17.83
Earnings From Continuing Operations	-25.5	-30.09	-26.96	-20.61	-17.83
Net Income	-25.5	-30.09	-26.96	-20.61	-17.83
Preferred Dividends & Other Adjustments	-	-	-	-	4.5
Net Income to Common	-25.5	-30.09	-26.96	-20.61	-22.33
Shares Outstanding (Basic)	126	126	127	117	11
Shares Outstanding (Diluted)	126	126	127	117	11
Shares Change (YoY)	-0.18%	-0.43%	8.27%	934.13%	33.09%
EPS (Basic)	-0.20	-0.24	-0.21	-0.18	-1.97
EPS (Diluted)	-0.20	-0.24	-0.21	-0.18	-1.97
Free Cash Flow	-21.05	-20.96	-20.79	-16.48	-11.58
Free Cash Flow Per Share	-0.17	-0.17	-0.16	-0.14	-1.02
EBITDA	-27.6	-31.35	-27.68	-20.5	-14.56
D&A For EBITDA	0.02	0.02	0.01	0.02	0.05
EBIT	-27.62	-31.38	-27.69	-20.52	-14.61

Updated Mar 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q